BeiGene Ltd ( (HK:6160) ) has issued an announcement.
BeiGene, Ltd. has filed a Form F-6 registration statement with the U.S. Securities and Exchange Commission to register American Depositary Shares (ADSs), each representing thirteen ordinary shares of the company. This filing is part of BeiGene’s strategic efforts to enhance its market presence and accessibility to investors, potentially impacting its financial operations and stakeholder interests.
More about BeiGene Ltd
BeiGene, Ltd. is a biotechnology company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. The company operates in the biopharmaceutical industry and is committed to improving treatment outcomes and access for patients globally.
YTD Price Performance: 38.74%
Average Trading Volume: 5,371,822
Technical Sentiment Signal: Sell
Current Market Cap: HK$222.7B
Learn more about 6160 stock on TipRanks’ Stock Analysis page.